Drugs.com - Pharma Industry News

Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis

THURSDAY, March 27, 2025 -- Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK inhibitor-naive patients, according to a study published...

Mar 27, 2025 - 18:44
 0
Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis
THURSDAY, March 27, 2025 -- Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK inhibitor-naive patients, according to a study published...
Read More

Tags:

Previous Article

Study Looks at Recovery Potential in Comatose Patients Who Died After Halting Li...

Next Article

Use of Parallel Transmit 7T MRI Changes Management for Epilepsy Surgery

Related Posts

Plant-Based Diets Increase Odds of Healthy Aging

Plant-Based Diets Increase Odds of Healthy Aging

Mar 24, 2025  0

Urine Test Sensitive for Renal Cancer Recurrence After Surgery

Urine Test Sensitive for Renal Cancer Recurrence After ...

Mar 26, 2025  0

Uptake of Supportive Care Low for Patients With Advanced Cancer

Uptake of Supportive Care Low for Patients With Advance...

Feb 28, 2025  0